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A B S T R A C T
Purpose
The Microarray Innovations in Leukemia study assessed the clinical utility of gene expression
profiling as a single test to subtype leukemias into conventional categories of myeloid and
lymphoid malignancies.
Methods
The investigation was performed in 11 laboratories across three continents and included 3,334
patients. An exploratory retrospective stage I study was designed for biomarker discovery and
generated whole-genome expression profiles from 2,143 patients with leukemias and myelodys-
plastic syndromes. The gene expression profiling–based diagnostic accuracy was further validated
in a prospective second study stage of an independent cohort of 1,191 patients.
Results
On the basis of 2,096 samples, the stage I study achieved 92.2% classification accuracy for all 18
distinct classes investigated (median specificity of 99.7%). In a second cohort of 1,152 prospec-
tively collected patients, a classification scheme reached 95.6% median sensitivity and 99.8%
median specificity for 14 standard subtypes of acute leukemia (eight acute lymphoblastic leukemia
and six acute myeloid leukemia classes, n  693). In 29 (57%) of 51 discrepant cases, the
microarray results had outperformed routine diagnostic methods.
Conclusion
Gene expression profiling is a robust technology for the diagnosis of hematologic malignancies
with high accuracy. It may complement current diagnostic algorithms and could offer a reliable
platform for patients who lack access to today’s state-of-the-art diagnostic work-up. Our comprehen-
sive gene expression data set will be submitted to the public domain to foster research focusing on
the molecular understanding of leukemias.
J Clin Oncol 28:2529-2537. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Microarray studies have identified gene expression
signatures associated with distinct clinical subtypes
of leukemia.1 In studies of both pediatric and adult
acute lymphoblastic leukemia(ALL),patients canbe
classified according to specific gene expression
profiles.2-10 Characteristic signatures, for example,
those identified in acute myeloid leukemia (AML)
subtypeswith t(15;17), t(8;21), inv(16), or t(11q23)/
MLL, have been confirmed not only with different
DNA oligonucleotide microarray designs,11,12 but
also byusing aprincipally differentmicroarray tech-
nology.13 Furthermore, gene expression analyses of
nearly 1,000 patients led to the discovery of distinct
expression signatures, not only specific among adult
acute and chronic leukemia subtypes, but also in
comparison to nonleukemia and healthy bonemar-
row specimens.14
Because microarray assays can analyze the ex-
pressionofmultiple genes inparallel, theyhavebeen
proposed as a robust test method for diagnostic us-
age in a clinical laboratory.However, publisheddata
in this area have been derived from relatively small,
single-center studies involving archival samples.
Here, we report results from 3,334 patients who
were analyzed as part of an international study
group formed around the European LeukemiaNet
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(ELN) in 11 laboratories across three continents (seven from theELN,
three fromtheUnitedStates, andone inSingapore).The collaborative
Microarray Innovations in Leukemia (MILE) study programwas de-
signed to assess the clinical accuracy of gene expression profiles (com-
pared with current routine diagnostic work-up) of 16 acute and
chronic leukemia subclasses, myelodysplastic syndromes (MDSs),
anda so-called“noneof the target classes” control group that included
nonmalignant disorders and normal bonemarrow.
METHODS
Study Design
There were two stages in the MILE research study: a retrospective bi-
omarker discovery phase (stage I) using commercially available whole-
genomemicroarrays (HG-U133Plus 2.0; Affymetrix, SantaClara, CA) and an
independent validation phase (stage II) that was performed in a prospective
manner using a newly designed custom chip (AmpliChip Leukemia; Roche
MolecularSystems,Pleasanton,CA).Beforeeachstageof the study,designated
laboratory operators at each site were trained on the corresponding sample
preparation protocol and had demonstrated proficiency in the technology.15
The individual steps of the sample preparation workflow are available online.
All samples in this study were obtained from untreated patients at the time of
diagnosis. Cells used for microarray analysis were collected from the purified
fraction of mononuclear cells after Ficoll density centrifugation. The study
design adhered to the tenets of the Declaration of Helsinki and was approved
by the ethics committees of the participating institutions before its initiation.
The sponsor collected the anonymized patient data and performed the final
statistical analysis. All authors had full access to both the primary local mi-
croarray data and the final analysis.
Microarray Data Preprocessing and Exploratory Analyses
Data preprocessing included a summarization and quantile normaliza-
tion step to generate probe set level signal intensities for each microarray
experiment and was performed as previously described.16 Data visualization
and exploratory analyses were performed with Partek Genomics Suite soft-
ware version 6.3 (Partek, St Louis, MO) and R software version 2.5.1 (http://
www.r-project.org), including the Affy, MADE4, and Heatplus packages.17 A
margin tree graphwas generated following amethod previously established in
the use of high-dimensional classification of cancer microarray data.18 The
margin tree is learned in an unbiased manner and emerges naturally in a
mathematical procedure. All microarray raw data were deposited in Na-
tional Center for Biotechnology Information’s Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo/) under series accession num-
ber GSE13204.19
Custom Chip Design
The AmpliChip Leukemia researchmicroarray was specifically custom-
ized for the classification of leukemias.20 The chip contained 1,480 distinct
probe sets with 11-m feature size. The source of the probe set design was
based on the commercially available Affymetrix HG-U133 Plus 2.0 microar-
ray. One thousand four hundred fifty-seven probe sets were used for generat-
ing normalized signal intensities of disease-related genes, and 23 probe sets
interrogated control sequences and housekeeping genes. Three hundred
ninety-eight probe sets were tiled in triplets to increase the robustness of the
algorithm performance.
Algorithm Training for Classification Analysis
For multiclass classification, an all-pairwise approach was performed
using trimmed mean of differences between perfect match and mismatch
intensities with quantile normalization (DQN) signals.16 For 18 classes, there
were 153 distinct class pairs. For every class pair, a linear binary classifier was
formedwithsupportvectormachines.21,22For this classifier,nwas thenumber
of used probe sets. The classifier for class pair (i, j) (i j) consisted of (n 1)
coefficients, w[0; i, j], w[1; i, j], …, w[n; i, j]. Normalized expression signals
weredenotedbyx[1],…,x[n].Thedecision function forclasspair (i, j)was f(x;
i, j)w[0; i, j]w[1; i, j] * x[1]…w[n; i, j] * x[n]. If f(x; i, j) 0, a vote
was added to class i; if f(x; i, j)0, a votewas added to class j. If f(x; i, j)0, 0.5
voteswere added to class i, and0.5 voteswere added to class j. This processwas
repeated forall classpairs toobtain thevotes forall classes. If therewasaunique
Table 1. Overview of Stage I Samples
Class Diagnosis
Study Center (No. of samples)
Total No. of Samples1 2 3 4 5 6 7 8 9 10 11
C1 Mature B-ALL with t(8;14) 2 2 2 5 1 1 13
C2 Pro-B-ALL with t(11q23)/MLL 6 12 10 1 33 5 1 2 70
C3 c-ALL/pre-B-ALL with t(9;22) 27 10 15 7 8 39 4 12 122
C4 T-ALL 42 1 19 17 4 38 44 9 174
C5 ALL with t(12;21) 16 23 1 18 58
C6 ALL with t(1;19) 5 11 2 9 3 1 5 36
C7 ALL with hyperdiploid karyotype 1 14 2 14 2 7 40
C8 c-ALL/pre-B-ALL without t(9;22) 50 29 28 2 59 42 3 24 237
C9 AML with t(8;21) 7 1 2 13 5 1 11 40
C10 AML with t(15;17) 2 2 8 5 4 3 13 37
C11 AML with inv(16)/t(16;16) 6 4 3 4 6 3 2 28
C12 AML with t(11q23)/MLL 4 4 5 6 17 1 1 38
C13 AML with normal karyotype  other abnormalities 2 60 1 12 63 117 19 9 41 27 351
C14 AML complex aberrant karyotype 4 3 2 28 2 1 6 2 48
C15 CLL 15 35 41 81 45 32 199 448
C16 CML 5 44 15 12 76
C17 MDS 28 71 3 1 56 44 3 206
C18 Non-leukemia and healthy bone marrow 19 19 17 16 3 74
Total 2,096
NOTE. Two thousand ninety-six high-quality analyses were performed by 11 different study centers from seven countries across three continents. Eighteen
diagnostic gold standard categories are given by their class subtype labels of C1 to C18 and are listed for each participating laboratory (laboratories 1 to 11).
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia;MLL, myeloid/lymphoid or mixed-lineage leukemia; pre, precursor; c-ALL, childhood acute lymphoblastic
leukemia; T-ALL, T-cell acute lymphoblastic leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML,
chronic myelogenous leukemia; MDS, myelodysplastic syndrome.
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classwith themaximal vote, the callwas thisparticular class. If therewas a tieof
two or more classes with the maximal vote, an indeterminable call was as-
signed. The step of probe set selection was included in every cross-validation
run andwas performed to select the top 100 differentially expressed probe sets
with themaximalabsolutevaluesof t statistic foreveryclasspair. Subsequently,
the union of the selected probe sets of all class pairs was used for every
binary classifier.
RESULTS
Marker Discovery Phase Using
Whole-Genome Microarrays
During stage I of the study, 2,143 whole-genome microarray
analyses were performed. Each center had previously diagnosed the
samples as part of their daily routine diagnostic work-up, using their
local gold standard diagnostic methods, including cytomorphology,
immunophenotyping, cytogenetics, and other molecular genetic
tests. Each specimen then was assigned based on these previous
diagnostic test reports to one of the 18MILE study categories (C1 to
C18) for microarray analysis. Seventeen classes had been selected as
representing standard subclasses of acute and chronic leukemias, as
well as MDS. Class 18 included healthy bone marrow specimens and
nonleukemia conditions, such as megaloblastic anemia, hemolysis,
iron deficiency, or idiopathic thrombocytopenic purpura, and was
considered to be none of the target classes.
Despite strict quality criteria, 47 samples (2.2%) had to be ex-
cluded as a result of low technical quality of the gene expression
profiles. The remaining 2,096 samples are listed in Table 1. The sam-
pleswere not equally distributed among the participating laboratories
but were variably contributed depending on each center’s expertise
(eg, center 10 included chronic lymphocytic leukemia [CLL] speci-
mens and center 7 analyzed cases of pediatric leukemias). Consistent
with the actual incidence of the respective categories, lower sample
numbers were submitted for certain uncommon subtypes, including
mature B-cell ALL with t(8;14) (C1) and AML with inv(16)/t(16;16)
(C11). All other classes comprisedmore than 30 samples each (range,
36 to 448 samples).
Several approaches were selected to perform exploratory data
analyses. First, supervised hierarchical clustering was performed to
confirm whether the selected classes would indeed harbor distinct
gene expression signatures for the 2,096 whole-genome gene expres-
sion profiles. Strong differenceswere observed in the respective signa-
tures for classes C1 to C18 (Fig 1).
Next, a method developed by Tibshirani and Hastie,18 estab-
lished for high-dimensional classification of cancer microarray data,
was applied. Thismethod not only produces a classifier, but also gives
output graphs, so-called margin trees, that indicate the relatedness of
different disease entities.18 A hierarchical data tree applied to our data
set of 2,096 samples is shown in Figure 2, where two major branches
can be observed, one that contains mainly the B-lineage ALL catego-
ries and a second larger branch that contains themyeloid and chronic
leukemias. MDS samples and nonleukemia specimens were also lo-
cated in this larger branch. The binary decision tree and the hierarchi-
cal relationship among the classes can be interpreted in a top-down
manner anddemonstrated ameaningful organizationof the 16 leuke-
mia classes and MDS on the basis of their respective gene expres-
sion signatures.
The series of 1,292 acute leukemia samples represented in the
stage I cohort were further evaluated for gene signatures that would
serve as a so-called virtual immunophenotype. Fourteendistinct types
of acute leukemias (C1 toC14)aredisplayed inaheatmapof thegenes
encoding21differentiationantigens routinelyused forflowcytometry
(Fig 3A). For each of the threemajor lineages involved in leukemia (B
Class:
C18C17C16C15C14C13C12C11C10C9C8C7C6C5C4C3C2C1
Fig 1. Supervised hierarchical cluster-
ing. The exploratory whole-genome clus-
tering analysis was performed for all
classes (C1 to C18 in ascending order)
including 2,096 samples from stage I. For
every class pair, the top 100 differentially
expressed probes sets with the largest
absolute values of t statistic were se-
lected. The union of these sets contained
3,556 probe sets used in the clustering.
Microarray-Based Subclassification of Leukemias
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cells, T cells, andmyeloid cells), distinct clusters were observed based
on the gene expression signature of the corresponding antigens.
Subtype-specific patterns were identifiable, for example, the low ex-
pression of HLA-DR  and  antigens in AML with t(15;17) (C10).
Such subtype-specific patterns became even more obvious when vir-
tual immunophenotypedatawere represented as a series of individual
box plots for each of the 14 classes of acute leukemias (Fig 3B).
Algorithm Training for Classification Analysis
The classificationperformance of retrospective samples of stage I
was investigated next by developing a prediction algorithm based on
linear discriminant classification. To estimate the performance of the
classifiers, three independent 30-fold cross-validations were used. For
every possible pair of comparisons between the 18 distinct classes, the
top 100 probe sets with the largest absolute values of t statistics were
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Margin tree classification is a supervised
multiclass support vector machine classi-
fication method.18 The margin tree pro-
gram was applied to the stage I data set
of 2,096 samples, characterized by their
18 class subtype labels (C1 to C18), and
was based on 54,630 probe sets. B-ALL,
B-cell acute lymphoblastic leukemia; MLL,
myeloid/lymphoid or mixed-lineage leuke-
mia; pre, precursor; c-ALL, childhood acute
lymphoblastic leukemia; T-ALL, T-cell acute
lymphoblastic leukemia; ALL, acute lympho-
blastic leukemia; AML, acutemyeloid leuke-
mia; kt., karyotype; abn., abnormality; CLL,
chronic lymphocytic leukemia; CML, chronic
myelogenous leukemia; MDS, myelodysplas-
tic syndrome.
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A
Fig 3. Virtual immunophenotypes for 1,292 acute leukemia specimens from stage I of the Microarray Innovations in Leukemia study. (A) Microarray gene expression
signal intensities of 21 differentiation antigens currently tested in flow cytometry for the diagnosis of leukemia represented by 32 probe sets. (B) Gene expression
intensities for CD3G, CD19, CD33, and HLA-DRA. Each dot represents the data from a single microarray profile. B-ALL, B-cell acute lymphoblastic leukemia; T-ALL,
T-cell acute lymphoblastic leukemia; AML, acute myeloid leukemia.
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selected. The union of all selected probe sets was then used for subse-
quent classification of all class pairs.
When all 2,096 samples from stage I were included, the classifi-
cation analysis of their whole-genome gene expression profiles dem-
onstrated that overall, in 92.2% of samples, the gene expression
classification was concordant with the initial gold-standard diagnosis
(99.6%specimenswithauniquecall).Thismeans that a smallnumber
of samples received indeterminable calls as a result of ties of majority
votes of the classifier (Table 2). In seven of the 18 classes, the concor-
dance was 94.6%. As detailed in the confusionmatrix, lower sensi-
tivities in predicting leukemia types were observed, in particular, for
classes C1, C7, C8, C12, and C14. This can largely be explained by the
biologic heterogeneity within the class and the lack of standardized
gold-standard definitions. However, it is notable that all analyzed
classes showed specificities greater than 98.1% and that, overall, all 18
analyzed classes could be predictedwith amedian sensitivity of 92.1%
and amedian specificity of 99.7%.
Classification Algorithm Testing on an Independent
Patient Cohort
After completion of stage I, the participating laboratories pro-
spectively collected 1,191 samples as an independent validation co-
hort. Similar to stage I, only samples were included where a full gold
standard diagnostic work-up had been completed by the laboratories
so that each specimen would be grouped into one of the 18 study
classes beforemicroarray analysis. Experimentswereperformedusing
a standardized procedure and a customized chip, the AmpliChip
Leukemia microarray. Of the 1,191 stage II gene expression profiles,
1,152 (96.7%) passed the quality criteria and were further processed
formicroarray classification.When using a predictionmodel, trained
on thewhole-genomegeneexpressionprofiles fromstage I, theoverall
accuracy for all 18 classes of this independent test cohort using the
customchipwas 88.1% (overall call rate, 99.6%). Similar to the stage I
data set, miscalls were predominantly observed for the interface of
C7/C8 inALL and in theMDS-AMLcontinuum.The predicted accu-
racies for CLL, chronic myelogenous leukemia, and MDS in stage II
were 98.7%, 93.0%, and 81.5%, respectively.
When focused on an acute leukemia–type diagnostic algorithm,
the overall prediction accuracy for all called samples markedly in-
creased to 91.5% (overall call rate, 98.1%).As shownby the confusion
matrix in Table 3, 100% correct predictions were observed for five
leukemia types (C1, C2, C6, C9, and C11), each of which represented
leukemias with discrete disease-defining fusion genes. Lower accura-
cies were observed for the interface of C7/C8 in ALL, as well as for
more intrinsically heterogeneous subtypes such as C12 and C14 in
AML. Nonetheless, eight of the 14 represented acute leukemia types
were concordant with the gold standard in 95.0% of the analyses.
When summarized over all acute leukemia subtypes, this focused
classification scheme resulted in a 95.6% median sensitivity and a
99.8% median specificity for the eight ALL and six AML classes
included in the classifier (C1 to C14, n 693). This result reinforces
the strength of microarray technology, which offers high positive
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prediction accuracy based on a standardized, robust, and objective
molecular assay.
During the process of clarifying discrepant results (ie, comparing
microarray classifier predictions against the gold-standard diagnoses
submitted to the study database), in 51 (7.4%) of 693 acute leukemia
samples, discrepancies could be resolved. A first category of 22 (43%)
of 51 discrepant samples were explained either because of erroneous
entries into case report formsorwrong sample labels (n13, 25%)or
Table 2. Whole-Genome Classification Confusion Matrix
GS/Call
Class Prediction
Average No.
of IDC As a
Result of
Ties of
Majority
Votes
Total No.
of
Specimens
in Every
Class CR
Sensitivity
for Called
Specimens
Specificity
for Called
SpecimensC1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 C17 C18
C1/GS 9.3 — — — — — — 0.7† — — — — 0.3† — — — 0.3† 1† 1.3 13 0.897 0.800 0.999
C2/GS — 70 — — — — — — — — — — — — — — — — 0 70 1.000 1.000 0.998
C3/GS — — 114.3 — — — 0.3† 7.3† — — — — — — — — — — 0 122 1.000 0.937 0.997
C4/GS — — — 166.3 — — — 1.7† — — — — 4† — — — 0.3† 0.7† 1 174 0.994 0.961 0.997
C5/GS — — — — 53.7 — — 4.3† — — — — — — — — — — 0 58 1.000 0.925 0.997
C6/GS — 2† — — — 33 — 1† — — — — — — — — — — 0 36 1.000 0.917 1.000
C7/GS — — — — — — 30.3 9.7† — — — — — — — — — — 0 40 1.000 0.758 0.995
C8/GS 1† 3† 5.3† 1† 6† — 10.7† 205.3 — — — — 0.3† 1† 1† — 1.7† — 0.7 237 0.997 0.869 0.985
C9/GS — — — — — — — — 40 — — — — — — — — — 0 40 1.000 1.000 1.000
C10/GS — — — — — — — — — 35 — — 1† — — — 1† — 0 37 1.000 0.946 1.000
C11/GS — — — — — — — — — — 28 — — — — — — — 0 28 1.000 1.000 1.000
C12/GS — — — 1† — — — — — — — 32 5† — — — — — 0 38 1.000 0.842 0.999
C13/GS 1† — — 4.3† — — — 3† — 1† — 2† 311.3 9.7† 1.3† 0.7† 15.3† — 1.3 351 0.996 0.890 0.982
C14/GS — — — — — — — — — — — — 9.3† 35.7 — — 2.7† — 0.3 48 0.993 0.748 0.995
C15/GS — — — — — — — — — — — — 0.7† — 446 — 0.3† — 1 448 0.998 0.998 0.998
C16/GS — — 1† — — — — — — — — — — — — 72 0.3† 2.7† 0 76 1.000 0.947 0.999
C17/GS — — — — — — — — — — — — 11† — — — 184.3 7.7† 3 206 0.985 0.908 0.981
C18/GS — — — — — — — 1† — — — — — — 1† 1† 14† 57 0 74 1.000 0.770 0.994
NOTE. Classification prediction results for 2,096 samples from stage I as analyzed by three 30-fold cross validations. Gold standard classes are given in rows C1/GS
to C18/GS; the columns C1 to C18 list the average numbers of calls, rounded with up to 1 decimal place, for every class in three independent runs of
cross-validations. This model uses trimmed mean of differences between perfect match and mismatch intensities with quantile normalization (DQN) signal
intensities obtained from HG-U133 Plus 2.0 microarrays.
Abbreviations: IDC, indeterminable calls; CR, call rate (No. of specimens–IDC)/No. of specimens; GS, gold standard.
Values indicate correct prediction results.
†Values represent misclassifications for each class.
Table 3. Independent Testing Set of Acute Leukemias
GS/Call
Class Prediction
Average No.
of IDC As a
Result of
Ties of
Majority
Votes
Total No.
of
Specimens
in Every
Class CR
Sensitivity
for Called
Specimens
Specificity
for Called
SpecimensC1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14
C1/GS 4 — — — — — — — — — — — — — 1 5 0.800 1.000 0.999
C2/GS — 23 — — — — — — — — — — — — 0 23 1.000 1.000 0.998
C3/GS — — 53 — — — — 8† — — — — 1† — 0 62 1.000 0.855 0.995
C4/GS — — — 75 1† — — 1† — — — — 1† — 1 79 0.987 0.962 0.992
C5/GS — — — — 59 — — 5† — — — — — — 0 64 1.000 0.922 0.995
C6/GS — — — — — 10 — — — — — — — — 0 10 1.000 1.000 0.997
C7/GS — — — — — — 22 12† — — — — — — 1 35 0.971 0.647 0.989
C8/GS 1† 1† 2† — 2† 2† 7† 141 — — — — — — 2 158 0.987 0.904 0.950
C9/GS — — — — — — — — 16 — — — — — 0 16 1.000 1.000 1.000
C10/GS — — — — — — — — — 19 — — 1† — 0 20 1.000 0.950 0.998
C11/GS — — — — — — — — — — 20 — — — 0 20 1.000 1.000 1.000
C12/GS — — — 1† — — — — — — — 15 1† — 0 17 1.000 0.882 1.000
C13/GS — — 1† 3† — — — — — 1† — — 148 1† 6 160 0.963 0.961 0.985
C14/GS — — — 1† — — — — — — — — 4† 17 2 24 0.917 0.773 0.998
NOTE. Classification prediction results for 693 prospectively collected acute leukemia samples from stage II. Gold standard classes are given in rows C1/GS to
C14/GS; the prediction results are displayed for each sample in columns C1 to C14.
Abbreviations: IDC, indeterminable calls; CR, call rate (No. of specimens–IDC)/No. of specimens; GS, gold standard.
Values indicate correct prediction results.
†Values represent misclassifications for each class.
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because the respective diagnoses were revised after central indepen-
dent expert review of karyotypes using the definition of AML with
complex aberrant karyotypes from Schoch et al23 (n 9, 18%).
A second category of 29 (57%)of 51 discrepant samples could be
interpretedas samples inwhich the chip-basedpredictionhadoutper-
formed the laboratories’ own gold standard diagnostic result (overall,
29of 693 samples; 4.2%).These sampleswere split between specimens
in which subsequent retesting of leftover material confirmed the pre-
dicted acute leukemia subtype as classified by themicroarray (n 14)
and specimens in which re-evaluation of initial diagnostic reports
includingmorphologyorDNAindexvalues led to theconfirmationof
the microarray classification result (n 15). More detailed informa-
tion on the discrepant results analyses performed on these samples is
available online (Appendix Tables A1-A3 and Figures A1-A4, on-
line only).
DISCUSSION
In 2005, the InternationalMILE StudyGroupwas formed around the
ELN (Gene Expression Profiling Working Group) in 11 laboratories
across three continents. In two stages, the clinical accuracy of gene
expressionprofiles of 16 acute and chronic leukemia subclasses,MDS,
and a so-called “none of the target classes” control group was com-
paredwith current routinediagnosticwork-up in3,334patients.Gold
standard diagnostic methods were not standardized between centers.
Each center integrated the available results from their own laboratory
workflow and assigned each sample into one of the 18 MILE study
microarray categories.
In stage I of the study, only 2.2% of samples failed the strict
quality criteria, leaving 2,096 of 2,143 samples to be used in the train-
ingof a robustdiagnostic classificationalgorithm.Asdemonstratedby
various exploratory data analyses, each of the 18 diagnostic categories
was characterized by a specific underlying gene expression program.
The accuracy of this training cohortwas estimated by cross-validation
andwas 92.2% for the 18 classes (median specificity, 99.7%). In seven
of the 18 classes, the concordance was  94.6%. A high prediction
precision of 100% was observed, in particular, for the group of acute
leukemias with specific chromosomal aberrations [eg, as demon-
strated for pro-B-ALL with t(11q23)/MLL or the core binding factor
leukemias AML with t(8;21) or AML with inv(16)/t(16;16)]. Lower
sensitivitieswere seen inentitieswithbiologicheterogeneitywithin the
class (eg, AML with a complex aberrant karyotype [74.8%] or ALL
with ahyperdiploidkaryotype [75.8%]).However, it is notable that all
analyzed classes showed specificities greater than 98.1% and that,
overall, all 18 analyzed classes could be predicted with a median sen-
sitivity of 92.1% and a median specificity of 99.7%. Thus, in terms of
sensitivity and specificity, the gene expression results alone compared
favorably with the laboratories’ own gold-standard classification.
The potential clinical utility of microarray-based diagnostics
was then validated in stage II including another 1,152 patients, a
cohort that represented an independent and blinded validation set
for the classification algorithms developed in stage I. Overall, in
stage II, the observed accuracy of the classifier prediction across all
18 classes was 88.1%. The accuracy increased to 91.5% when fo-
cused on acute leukemias, representing all 14 distinct classes. In
eight of the 14 represented acute leukemia classes, microarray diag-
noses were concordant with the gold standard diagnoses in 95.0%
of the analyses.
To our knowledge, this is thus far the largest gene expression
microarray profiling study in hematology and oncology, and it clearly
underlines the robust performance of this method and demonstrates
thepossibilityof completely standardized laboratoryprocedures com-
bined with sophisticated data algorithms. This is in contrast to other,
far more subjective methods routinely used for leukemia diagnosis
today, such as cytomorphology andmetaphase cytogenetics. The next
step would now be an objective and unbiased discussion on how to
positionmicroarray technology in a routine diagnostic workflow and
whether it is suitable to helpfully support or even replace some of the
existing gold-standard techniques. For example, an array-based test
cannot, in all cases, replacemultiparameter flow cytometry or reverse
transcriptase polymerase chain reaction–based detection of molecu-
lar fusion genes, which is routinely applied to define the starting point
for clinically relevant detection of minimal residual disease.24,25
In one possible scenario, one could restrict the microarray tech-
nique to the classificationof acute leukemiasbecauseCLLandchronic
myelogenous leukemia are readily diagnosed by standard immuno-
phenotyping, cytogenetics, and molecular tests. An acute leukemia
classificationmicroarraymay then have utility in patients for whom a
conventional cytogenetic analysis is not available, either because of no
analyzable mitoses or poor quality of banded chromosomes.26,27
Although our study concept had to define up front the most
necessary leukemia entities and not all recurrent cytogenetic subtypes
according to the newWHO classification of 200828 were represented
by the actual data set,most subtypeswith current clinical relevance are
covered.Asa further intendeduse, thismicroarray techniquemayalso
serve to classify leukemia in developing countries that currently lack
expertise to perform the current labor-intensive and sophisticated
diagnostic approaches.
Finally, the investigators of the MILE study submitted their
gene expression database to the public domain (Gene Expression
Omnibus Accession No. GSE13204) to foster research elucidating
the molecular understanding of leukemias. Future refinements need
to include additional signatures for prognostically important sub-
sets of patients with AML with normal cytogenetics.12,13,29,30 Such
signatures have already been tentatively identified by a number of
groups.31-37 Microarray analysis can even be applied to investigate
expression signatures of other novel markers such as WT1,38 detect a
specific pattern for RUNX1-mutated AML,39 and discover predictive
signatures for response to both currently used and novel targeted
treatment regimens.
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